Clinical Trial Update: A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing CNI-free versus standard regimen in new heart transplant recipients to assess renal tolerability, efficacy, and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2018-06-25